PCRX

Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

Wall Street analysts forecast PCRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCRX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pacira Biosciences Inc revenue for the last quarter amounts to 179.52M USD, increased 6.49 % YoY.

Pacira Biosciences Inc. EPS for the last quarter amounts to 0.12 USD, decreased -103.86 % YoY.

Pacira Biosciences Inc (PCRX) has 790 emplpoyees as of January 09 2026.

Today PCRX has the market capitalization of 1.12B USD.